PATENT CLAIM ANALYSIS

Application Number: 15882857
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "069600"]

Abstract:
Polypeptides having target levels of C-terminal variants are described.

Claim (Index 43):
A method of manufacturing a preparation of adalimumab, comprising:\n culturing a cell in a medium comprising 1.5 g/L arginine to 20 g/L arginine under conditions in which the cell expresses adalimumab; isolating the adalimumab, thereby producing a preparation of adalimumab; and formulating the preparation into a drug product if the preparation meets a target value of one or more C-terminal variants of adalimumab, wherein the C-terminal variants differ in amino acid sequence only by the presence or absence of a lysine at their carboxyl termini, wherein the C-terminal variants comprise one or more of a K1 lysine variant and a K2 lysine variant, wherein the K1 lysine variant has a lysine residue at one heavy chain C-terminus and wherein the K2 lysine variant has a lysine residue at each heavy chain C-terminus, and wherein (i) the target value of K1 lysine variants is 10% to 50% of the adalimumab preparation, or (ii) the target value of K2 lysine variants is 4% to 50% of the adalimumab preparation, or both (i) and (ii).

Metadata:
- Claim Count in Document: 47.0
- Percentile: 86.0
- Lexical Diversity: 1.0
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14149931', '14131005', '15261270', '13830976', '14923958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.4970609235118425
- 35 USC 102 Novelty (BERT): 0.5656429945578147
- Combined Prediction Score: 0.5039191306164398
- Mean Citation Score: 350.736994
- Max Citation Score: 431.57648
- Similarity Product: 419.82880922796255

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test